Lifeboat Foundation

Concerned about the war Ukraine? You’re not alone. Historian Yuval Noah Harari provides important context on the Russian invasion, including Ukraine’s long history of resistance, the specter of nuclear war and his view of why, even if Putin wins all the military battles, he’s already lost the war. (This talk and conversation, hosted by TED global curator Bruno Giussani, was part of a TED Membership event on March 1, 2022. Visit http://ted.com/membership to become a TED Member.)

Visit http://TED.com to get our entire library of TED Talks, transcripts, translations, personalized talk recommendations and more.

Continue reading “The War in Ukraine Could Change Everything | Yuval Noah Harari | TED” »

Anthony J. Ferrante, Global Head of Cybersecurity and Senior Managing Director, FTI Consulting, Inc.

Artificial intelligence (AI) models are built with a type of machine learning called deep neural networks (DNNs), which are similar to neurons in the human brain. DNNs make the machine capable of mimicking human behaviors like decision making, reasoning and problem solving. This presentation will discuss the security, ethical and privacy concerns surrounding this technology. Learning Objectives:1: Understand that the solution to adversarial AI will come from a combination of technology and policy.2: Learn that coordinated efforts among key stakeholders will help to build a more secure future.3: Learn how to share intelligence information in the cybersecurity community to build strong defenses.

//I personally think Putin is causing a massive (record breaking) humanitarian crisis on purpose with the bombings he has done in populated cities so far. Here is why (thread):\.

“I personally think Putin is causing a massive (record breaking) humanitarian crisis on purpose with the bombings he has done in populated cities so far. Here is why (thread):”

Public policy includes efforts by governmental as well as nongovernmental agencies (other than professional associations) to manage genetic enhancement. For example, the International Olympic Committee has a policy on performance-enhancing drugs in sport. In the United States, the Food and Drug Administration classified synthetic anabolic steroids as a restricted class of drugs, making it more difficult to get access to them. Such measures will not always be successful. Epoetin alfa (EPO) is a useful medication for the many people who suffer from chronic anemia, including people who must undergo regular renal dialysis. As a consequence, it is in very wide supply for legitimate therapeutic purposes, unlike the synthetic anabolic steroids. Imposing strict limitations on access to EPO would create an enormous inconvenience for the large number of people who benefit from the drug. The fact that some athletes are able to get their hands on EPO is an unintended consequence of having the drug widely available for legitimate therapeutic uses. The appropriate public policy will not be the same, necessarily, for every drug.

By “personal policy” we mean the moral understandings and social practices of individuals, parents, and families, including those moral convictions that would cause them to refrain from unwise or unfair use of genetic enhancement technologies. The Worth of a Child, for example, focuses on ethical issues involving children and parents.¹¹ How does one engage that sort of personal policy response? The means we have are limited but powerful: education, public dialogue, and the encouragement of ethical reflection.

In conclusion, there are four points worth reiterating. First, as we think about genetic enhancement, we should use a broad definition of genetic-enhancement technologies, not merely gene manipulation, but indirect genetic technologies, such as biosynthetic drugs. Second, we should try to anticipate the enhancement temptations of new therapies. Such anticipation may help us in shaping the marketing, availability, or other aspects of those technologies. Third, we should promote the adoption of appropriate public and professional policies. Finally, we should provide public education and dialogue to encourage personal ethical reflection on the appropriate uses and limits of genetic-enhancement technologies.

America’s Office of Science and Technology Policy, the National Science and Technology Council, and the National Security Council prioritize.

The Future Of Space Tech & Innovation — Dr. Joel Mozer Ph.D., Director of Science, Technology & Research, United States Space Force.

Dr. Joel Mozer is the Director of Science, Technology, and Research, United States Space Force (https://www.spaceforce.mil/).

Continue reading “Dr Joel Mozer, PhD — United States Space Force — Director of Science, Technology, and Research” »

Elon Musk has always said that Neuralink, the company he created in 2016 to build brain-computer interfaces, would do amazing things: Eventually, he says, it aims to allow humans to interact seamlessly with advanced artificial intelligence through thought alone. Along the way, it would help to cure people with spinal cord injuries and brain disorders ranging from Parkinson’s to schizophrenia.

Now the company is approaching a key test: a human clinical trial of its brain-computer interface (BCI). In December, Musk told a conference audience that “we hope to have this in our first humans” in 2022. In January, the company posted a job listing for a clinical trial director, an indication that it may be on track to meet Musk’s suggested timeline.

Musk has put the startup under unrelenting pressure to meet unrealistic timelines, these former employees say. “There was this top-down dissatisfaction with the pace of progress even though we were moving at unprecedented speeds,” says one former member of Neuralink’s technical staff, who worked at the company in 2019. “Still Elon was not satisfied.” Multiple staffers say company policy, dictated by Musk, forbade employees from faulting outside suppliers or vendors for a delay; the person who managed that relationship had to take responsibility for missed deadlines, even those outside their control.

Accelerating Research To Prevent & Cure Disease — Dr. Kevin Perrott, Ph.D., Founder & CEO, OpenCures; Co-Founder & Treasurer, SENS Research Foundation

Dr. Kevin Perrott, Ph.D. is Founder and CEO, OpenCures (https://opencures.org/), Adjunct Professor, University of Alberta, Co-Founder and Advisor, Oisin Biotechnologies, President, of Global Healthspan Policy Institute, and Co-Founder and Treasurer, SENS Research Foundation.

Continue reading “Dr Kevin Perrott, PhD — Founder & CEO — OpenCures — Accelerating Research To Prevent & Cure Disease” »